Group 1 - The core point of the report is the equity change of Shanghai Mengke Pharmaceutical Co., Ltd. (stock code: 688373), where Best Idea International Limited has reduced its shareholding from 10.49% to 8.91% through a block trade on September 4, 2025 [1][10][24] - Best Idea International Limited held 68,752,718 shares before the reduction, which accounted for 10.49% of the total shares [9] - The reduction involved the transfer of 10,313,714 shares, representing 1.57% of the total share capital of the company [10][24] Group 2 - The purpose of the equity change is attributed to the funding needs of Best Idea International Limited, leading to the decision to reduce its holdings [7] - There are no plans or agreements for Best Idea International Limited to increase or decrease its shareholding in the next 12 months [8] - The equity change does not require approval from relevant authorities and does not impose any additional conditions [3] Group 3 - The transfer price for the shares was set at 6.57 yuan per share, which is 85% of the average trading price over the previous 20 trading days [26] - The transfer process involved 102 institutional investors, including private equity funds, public funds, and securities companies [26][27] - The transfer will not result in any change in the control of the company, as Best Idea International Limited is not a controlling shareholder [11][19]

Core Viewpoint - Best Idea International Limited has reduced its stake in Amgen Pharmaceuticals by transferring 10.3137 million shares through a price inquiry, decreasing its ownership from 10.49% to 8.91% [1] Company Summary - The reduction in shareholding will not affect the control of the company [1] - The information disclosing party has no clear plans for further buying or selling shares in the next 12 months [1]

Overview - The report details the share transfer process of Shanghai Mengke Pharmaceutical Co., Ltd. (Mengke Pharma) from its shareholders JSR Limited and Best Idea International Limited to specific institutional investors [1][2][3]. Share Transfer Details - The maximum number of shares proposed for transfer is 22,946,192 shares, which represents 18,049,000 shares after the transfer, reducing JSR's holding from 5.88% to 4.70% and Best Idea's from 10.49% to 8.91% [2][3]. - The transfer method involves a price inquiry to specific institutional investors, adhering to the guidelines set by the Shanghai Stock Exchange [3][4]. Pricing Mechanism - The minimum transfer price is set at no less than 70% of the average trading price of Mengke Pharma's shares over the 20 trading days prior to August 21, 2025 [3][4]. - The final transfer price was determined to be 6.57 CNY per share, with a total subscription amount of 118,581,930 CNY [6][7]. Investor Participation - A total of 102 institutional investors received the subscription invitation, including private equity funds, public funds, securities companies, insurance companies, and qualified foreign institutional investors [5][6]. - The final allocation of shares was made to 10 institutional investors, with the total number of shares allocated being 18,049,000 [6][7]. Compliance and Verification - The report confirms that the share transfer process was conducted in compliance with relevant laws and regulations, ensuring fairness and transparency throughout the process [8][9]. - Both the transferor and transferee were verified to meet the necessary qualifications as stipulated by the regulatory guidelines [10][11].

上海盟科药业股份有限公司 简式权益变动报告书 上市公司名称：上海盟科药业股份有限公司 股票上市地点：上海证券交易所科创板 股票简称：盟科药业 股票代码：688373 信息披露义务人名称：Best Idea International Limited 通讯地址：香港铜锣湾百德新街 2-20 号恒隆中心 22 楼 住所：香港铜锣湾百德新街 2-20 号恒隆中心 22 楼 股份变动性质：股份减少 简式权益变动报告书签署日期：2025 年 9 月 4 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司收购管理办法》 （以下简称"《收购办法》"）、 《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》 （以下简称"《准则 15 号》"） 及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》的规定，本报告书已全面披露信息披露义 务人在盟科药业拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书 ...

Group 1 - JSR Limited and Best Idea International Limited are transferring shares of Shanghai Mengke Pharmaceutical Co., Ltd., with JSR's shareholding decreasing from 5.88% to 4.70% after the transfer [1][3] - The total number of shares being transferred is 18,049,000 at a price of 6.57 CNY per share, which is 85% of the average trading price over the last 20 days [6][8] - Best Idea International Limited's shareholding will decrease from 10.49% to 8.91%, bringing its ownership below 10% [5][3] Group 2 - The transfer process involved sending a subscription invitation to 102 institutional investors, including private equity funds and public fund management companies [7][8] - The final transfer price was confirmed at 6.57 CNY per share, with the transfer process adhering to regulatory requirements [8][9] - The transfer does not result in a change of control for the company, as the major shareholders remain unchanged [8][3]

证券代码：688373 证券简称：盟科药业 公告编号：2025-036 上海盟科药业股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 5%和 1%整数倍的提示性公告 JSR Limited（以下简称"JSR"）和 Best Idea International Limited（以下简称 "Best Idea"，二者合称"出让方"）保证向上海盟科药业股份有限公司（以下简称 "公司"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 一、 转让方情况 1 本次询价转让的价格为6.57元/股，转让的股票数量为18,049,000股。 公司控股股东、实际控制人、董事、监事及高级管理人员不参与本次询 价转让。 本次转让不会导致公司控股股东、实际控制人发生变化。 本次权益变动后，JSR Limited 及其一致行动人持股比例由8.69%减少至 7.51%，持有公司权益比例变动触及 1%的整数倍。 本次权益变动后，Best Idea International ...

上海盟科药业股份有限公司 简式权益变动报告书 上市公司名称：上海盟科药业股份有限公司 股票上市地点：上海证券交易所科创板 股票简称：盟科药业 股票代码：688373 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》的规定，本报告书已全面披露信息披露义 务人在盟科药业拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在盟科药业拥有权益的股份。 四、本次权益变动不需要取得相关主管部门批准，并不附加其他生效条件。 信息披露义务人名称：Best Idea International Limited 通讯地址：香港铜锣湾百德新街 2-20 号恒隆中心 22 楼 住所：香港铜锣湾百德新街 2-20 号恒隆中心 22 楼 股份变动性质：股份减少 简式权益变动报告书签署日期：2025 年 9 月 4 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》" ...

中国国际金融股份有限公司 关于上海盟科药业股份有限公司 股东向特定机构投资者询价转让股份的核查报告 中国国际金融股份有限公司（以下简称"中金公司""组织券商"）受上海盟科 药业股份有限公司（以下简称"盟科药业""公司""上市公司"）股东 JSR Limited 和 Best Idea International Limited（以下分别简称"JSR"和"Best Idea"，合称"出让 方"）委托，组织实施本次盟科药业股东向特定机构投资者询价转让（以下简称"本 次询价转让"）。 经核查，中金公司就本次询价转让的出让方、受让方是否符合《上海证券交易所 科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询价转让和 配售指引》"）要求，本次询价转让的询价、转让过程与结果是否公平、公正，是否符 合《询价转让和配售指引》的规定作出如下报告说明。 一、本次询价转让概述 （一）本次询价转让出让方 截至 2025 年 8 月 21 日，出让方所持公司股份的数量、占总股本比例情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | ...

| 11 | 2 19 | | 现在 | | --- | --- | --- | --- | | 000661 | 大香高 | +10.00% | 124.71 | | HIS SIG | -- | +6.99% | 56.50 | | 688062 | 迈克生物-U | +6.56% | 61.38 | | 300485 | 第 有V | +4.67% | 14.11 | | 301207 | K 7 2 2 1 | +3.76% | 19.05 | | 300357 | 我武生物 | +3.32% | | | 688278 | 特宣生物 | +2.01% | 87.63 | | 688687 | 圳天气 | +1.176 | 34.38 | | 887344 | 三元大 | +1.32% | 32.28 | | 688428 | 诺成健华-U | +1.21% | 30.00 | 9月2日早盘，创新药概念再度走强。百济神州一度涨超10%，股价续创历史新高。盟科药业涨超 10%，迈威生物、艾德药业、贝达药业、三生国健、南新制药等跟涨。 ...

Group 1 - The core announcement is about the approval of a new manufacturer, Chongqing Boteng Pharmaceutical Technology Co., Ltd., for the active pharmaceutical ingredient (API) of Contizolam, which is essential for the production of Contizolam tablets [1] - The API produced by Boteng is intended for the commercial production of Contizolam tablets, a new generation of oxazolidinone antibiotics developed by the company, used for treating complex skin and soft tissue infections [1] - The approval of the API registration indicates that Boteng's product meets national drug review technical standards, providing an additional supplier option for the commercial production of Contizolam tablets, thereby reducing reliance on a single supply path and enhancing market competitiveness [1] Group 2 - The new API supplier will help stabilize raw material supply and optimize production costs, which is crucial for expanding market share and responding to competition from similar products [1]